Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (106)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Anderson, L. V.
Right arrow Articles by Bushby, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, L. V.
Right arrow Articles by Bushby, K. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 8, 855-861, Copyright © 1999 by Oxford University Press

ARTICLES

Dysferlin is a plasma membrane protein and is expressed early in human development [published erratum appears in Hum Mol Genet 1999 Jun;8(6):1141]

LV Anderson, K Davison, JA Moss, C Young, MJ Cullen, J Walsh, MA Johnson, R Bashir, S Britton, S Keers, Z Argov, I Mahjneh, F Fougerousse, JS Beckmann and KM Bushby
Neurobiology Department, University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. l.v.b.anderson@ncl.ac.uk

Recently, a single gene, DYSF, has been identified which is mutated in patients with limb-girdle muscular dystrophy type 2B (LGMD2B) and with Miyoshi myopathy (MM). This is of interest because these diseases have been considered as two distinct clinical conditions since different muscle groups are the initial targets. Dysferlin, the protein product of the gene, is a novel molecule without homology to any known mammalian protein. We have now raised a monoclonal antibody to dysferlin and report on the expression of this new protein: immunolabelling with the antibody (designated NCL-hamlet) demonstrated a polypeptide of approximately 230 kDa on western blots of skeletal muscle, with localization to the muscle fibre membrane by microscopy at both the light and electron microscopic level. A specific loss of dysferlin labelling was observed in patients with mutations in the LGMD2B/MM gene. Furthermore, patients with two different frameshifting mutations demonstrated very low levels of immunoreactive protein in a manner reminiscent of the dystrophin expressed in many Duchenne patients. Analysis of human fetal tissue showed that dysferlin was expressed at the earliest stages of development examined, at Carnegie stage 15 or 16 (embryonic age 5-6 weeks). Dysferlin is present, therefore, at a time when the limbs start to show regional differentiation. Lack of dysferlin at this critical time may contribute to the pattern of muscle involvement that develops later, with the onset of a muscular dystrophy primarily affecting proximal or distal muscles.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
D. P. Millay, M. Maillet, J. A. Roche, M. A. Sargent, E. M. McNally, R. J. Bloch, and J. D. Molkentin
Genetic Manipulation of Dysferlin Expression in Skeletal Muscle: Novel Insights into Muscular Dystrophy
Am. J. Pathol., November 1, 2009; 175(5): 1817 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Kesari, M. Fukuda, S. Knoblach, R. Bashir, G. A. Nader, D. Rao, K. Nagaraju, and E. P. Hoffman
Dysferlin Deficiency Shows Compensatory Induction of Rab27A/Slp2a That May Contribute to Inflammatory Onset
Am. J. Pathol., November 1, 2008; 173(5): 1476 - 1487.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. Nguyen, G. Bassez, M. Krahn, R. Bernard, P. Laforet, V. Labelle, J. A. Urtizberea, D. Figarella-Branger, N. Romero, S. Attarian, et al.
Phenotypic Study in 40 Patients With Dysferlin Gene Mutations: High Frequency of Atypical Phenotypes
Arch Neurol, August 1, 2007; 64(8): 1176 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
L. Klinge, S. Laval, S. Keers, F. Haldane, V. Straub, R. Barresi, and K. Bushby
From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis
FASEB J, June 1, 2007; 21(8): 1768 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
I. Illa, N. De Luna, R. Dominguez-Perles, R. Rojas-Garcia, C. Paradas, J. Palmer, C. Marquez, P. Gallano, and E. Gallardo
Symptomatic dysferlin gene mutation carriers: Characterization of two cases
Neurology, April 17, 2007; 68(16): 1284 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. Fujita, Y. Kouroku, A. Isoai, H. Kumagai, A. Misutani, C. Matsuda, Y. K. Hayashi, and T. Momoi
Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II)
Hum. Mol. Genet., March 15, 2007; 16(6): 618 - 629.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Y. Huang, S. H. Laval, A. van Remoortere, J. Baudier, C. Benaud, L. V. B. Anderson, V. Straub, A. Deelder, R. R. Frants, J. T. den Dunnen, et al.
AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration
FASEB J, March 1, 2007; 21(3): 732 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Pradhan
Calf-head sign in miyoshi myopathy.
Arch Neurol, October 1, 2006; 63(10): 1414 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
N. L. Washington and S. Ward
FER-1 regulates Ca2+-mediated membrane fusion during C. elegans spermatogenesis
J. Cell Sci., June 15, 2006; 119(12): 2552 - 2562.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. J. Hernandez-Deviez, S. Martin, S. H. Laval, H. P. Lo, S. T. Cooper, K. N. North, K. Bushby, and R. G. Parton
Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3
Hum. Mol. Genet., January 1, 2006; 15(1): 129 - 142.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Wenzel, J. Zabojszcza, M. Carl, S. Taubert, A. Lass, C. L. Harris, M. Ho, H. Schulz, O. Hummel, N. Hubner, et al.
Increased Susceptibility to Complement Attack due to Down-Regulation of Decay-Accelerating Factor/CD55 in Dysferlin-Deficient Muscular Dystrophy
J. Immunol., November 1, 2005; 175(9): 6219 - 6225.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
L.-S. Ro, G.-J. Lee-Chen, T.-C. Lin, Y.-R. Wu, C.-M. Chen, C.-Y. Lin, and S.-T. Chen
Phenotypic Features and Genetic Findings in 2 Chinese Families With Miyoshi Distal Myopathy
Arch Neurol, October 1, 2004; 61(10): 1594 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Ho, C. M. Post, L. R. Donahue, H. G.W. Lidov, R. T. Bronson, H. Goolsby, S. C. Watkins, G. A. Cox, and R. H. Brown Jr
Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency
Hum. Mol. Genet., September 15, 2004; 13(18): 1999 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Cagliani, N. Bresolin, A. Prelle, A. Gallanti, F. Fortunato, M. Sironi, P. Ciscato, G. Fagiolari, S. Bonato, S. Galbiati, et al.
A CAV3 microdeletion differentially affects skeletal muscle and myocardium
Neurology, December 9, 2003; 61(11): 1513 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Takahashi, M. Aoki, M. Tateyama, E. Kondo, T. Mizuno, Y. Onodera, R. Takano, H. Kawai, K. Kamakura, H. Mochizuki, et al.
Dysferlin mutations in Japanese Miyoshi myopathy: Relationship to phenotype
Neurology, June 10, 2003; 60(11): 1799 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Campanaro, C. Romualdi, M. Fanin, B. Celegato, B. Pacchioni, S. Trevisan, P. Laveder, C. De Pitta, E. Pegoraro, Y. K. Hayashi, et al.
Gene expression profiling in dysferlinopathies using a dedicated muscle microarray
Hum. Mol. Genet., December 15, 2002; 11(26): 3283 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. J. Holzfeind, P. K. Grewal, H. A. Reitsamer, J. Kechvar, H. Lassmann, H. Hoeger, J. E. Hewitt, and R. E. Bittner
Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Largemyd mouse defines a natural model for glycosylation-deficient muscle - eye - brain disorders
Hum. Mol. Genet., October 2, 2002; 11(21): 2673 - 2687.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Gallardo, R. Rojas-Garcia, N. de Luna, A. Pou, R.H. Brown Jr., and I. Illa
Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients
Neurology, December 11, 2001; 57(11): 2136 - 2138.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Matsuda, Y. K. Hayashi, M. Ogawa, M. Aoki, K. Murayama, I. Nishino, I. Nonaka, K. Arahata, and R. H. B. Jr
The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle
Hum. Mol. Genet., August 1, 2001; 10(17): 1761 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Aoki, J. Liu, I. Richard, R. Bashir, S. Britton, S. M. Keers, J. Oeltjen, H. E. V. Brown, S. Marchand, N. Bourg, et al.
Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy
Neurology, July 24, 2001; 57(2): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Selcen, G. Stilling, and A. G. Engel
The earliest pathologic alterations in dysferlinopathy
Neurology, June 12, 2001; 56(11): 1472 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Fanin, E. Pegoraro, C. Matsuda-Asada, R.H. Brown Jr., and C. Angelini
Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy
Neurology, March 13, 2001; 56(5): 660 - 665.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. FRIGERI, G. P. NICCHIA, B. NICO, F. QUONDAMATTEO, R. HERKEN, L. RONCALI, and M. SVELTO
Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice
FASEB J, January 1, 2001; 15(1): 90 - 98.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
Z. Argov, M. Sadeh, K. Mazor, D. Soffer, E. Kahana, I. Eisenberg, S. Mitrani-Rosenbaum, I. Richard, J. Beckmann, S. Keers, et al.
Muscular dystrophy due to dysferlin deficiency in Libyan Jews: Clinical and genetic features
Brain, June 1, 2000; 123(6): 1229 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Muchir, G. Bonne, A. J. van der Kooi, M. van Meegen, F. Baas, P. A. Bolhuis, M. de Visser, and K. Schwartz
Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B)
Hum. Mol. Genet., May 22, 2000; 9(9): 1453 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. B. Davis, A. J. Delmonte, C. T. Ly, and E. M. McNally
Myoferlin, a candidate gene and potential modifier of muscular dystrophy
Hum. Mol. Genet., January 22, 2000; 9(2): 217 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
K. M. D. Bushby
The limb-girdle muscular dystrophies--multiple genes,multiple mechanisms
Hum. Mol. Genet., September 1, 1999; 8(10): 1875 - 1882.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Matsuda, M. Aoki, Y. K. Hayashi, M. F. Ho, K. Arahata, and R. H. Brown Jr.
Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy
Neurology, September 1, 1999; 53(5): 1119 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. M. D. Bushby
Making sense of the limb-girdle muscular dystrophies
Brain, August 1, 1999; 122(8): 1403 - 1420.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.